Mimotopes and Genzyme Pharmaceuticals to collaborate
Friday, 27 January, 2006
PharmAust's (ASX:PAA) subsidiary Mimotopes and US-based Genzyme Corporation have signed a strategic alliance agreement to provide a total suite of peptide products and services to both companies' customer bases.
The exclusive and global agreement commences on February 1, 2006.
Mimotopes will supply customers with research grade peptides and related services up to the point of lead candidate identification in pre-clinical applications.
Genzyme Pharmaceuticals, a business unit of Genzyme Corporation that develops and manufactures peptide and lipid products, will supply customers with identified lead candidate peptides for pre-clinical applications through to clinical and therapeutic grade peptides and related services.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
